Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Gemcitabine
Related studies linked through entity extraction aliases.
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
- Status
- RECRUITING
- Phase
- PHASE1
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
- Status
- RECRUITING
- Phase
- PHASE1
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE3
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Status
- RECRUITING
- Phase
- PHASE3
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3